Comparing Trivascular Technologies (TRIV) & The Competition

Trivascular Technologies (NASDAQ: TRIV) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its rivals? We will compare Trivascular Technologies to similar companies based on the strength of its earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Insider and Institutional Ownership

54.4% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 10.3% of shares of all “Medical Devices & Implants” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Trivascular Technologies and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trivascular Technologies -143.61% -766.90% -66.97%
Trivascular Technologies Competitors -100.14% -92.44% -29.75%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Trivascular Technologies and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trivascular Technologies 0 0 0 0 N/A
Trivascular Technologies Competitors 127 739 1041 10 2.49

As a group, “Medical Devices & Implants” companies have a potential upside of 42.69%. Given Trivascular Technologies’ rivals higher possible upside, analysts plainly believe Trivascular Technologies has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Trivascular Technologies and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Trivascular Technologies N/A N/A -2.04
Trivascular Technologies Competitors $1.67 billion $207.76 million 91.92

Trivascular Technologies’ rivals have higher revenue and earnings than Trivascular Technologies. Trivascular Technologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Trivascular Technologies rivals beat Trivascular Technologies on 8 of the 8 factors compared.

About Trivascular Technologies

Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company’s solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.

Receive News & Ratings for Trivascular Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trivascular Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.